Showing results (141-150 of 171) with videos related to

Sort By:
Pageof 18
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 9, 2025
Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) ImmunotherapyMarcel Wiesweg, Ali Alaffas, Anna Rasokat, et al.
Therapeutic Advances in Medical Oncology|September 15, 2022
Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre studyFoteinos-Ioannis Dimitrakopoulos, Giannis Mountzios, Petros Christopoulos, et al.
British Journal of Cancer|January 13, 2026
Diagnostic whole transcriptome sequencing in a series of 1233 FFPE solid tumor samplesMarkus Ball, Susanne Beck, Darius Wlochowitz, et al.
Current Oncology (Toronto, Ont.)|March 27, 2026
Real-World Treatment Patterns and Survival in Patients with ROS1-Positive Advanced Non-Small Cell Lung Cancer in Canada and EuropeWinson Y Cheung, Adam Lee, Helena Bote de Cabo, et al.
Lung Cancer (Amsterdam, Netherlands)|December 28, 2020
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, et al.
Lung Cancer (Amsterdam, Netherlands)|March 5, 2021
Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical fieldAnna-Lena Volckmar, Petros Christopoulos, Martina Kirchner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 14, 2023
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung CancerPhilip Bischoff, Martin Reck, Tobias Overbeck, et al.
Cancer Letters|February 21, 2025
Intracellular and extracellular activities of V-domain Ig-containing suppressor of T cell activation (VISTA) modulated by immunosuppressive factors of tumour microenvironmentMaryam Abooali, Stephanie Schlichtner, Xi Lei, et al.
International Journal of Cancer|January 18, 2019
Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg casesAnna-Lena Volckmar, Jonas Leichsenring, Martina Kirchner, et al.
Translational Lung Cancer Research|May 20, 2021
Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinomaDaniel Kazdal, Eugen Rempel, Cristiano Oliveira, et al.
Pageof 18